[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564359":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":43,"responsibleParty":62,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":46,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Oxford","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"losartan","EXPERIMENTAL","oral single-dose losartan potassium (Cozaar; 50mg)",[13],"Drug: Losartan potassium 50mg",{"label":15,"type":16,"description":17,"interventionNames":18},"placebo","PLACEBO_COMPARATOR","Microcellulose placebo in identical capsule",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Losartan potassium 50mg","Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Single tablet encapsulated identically to losartan",[15],[32],{"name":33,"affiliation":5,"role":34},"Andrea Reinecke, PhD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+44 01865 618320","andrea.reinecke@psych.ox.ac.uk",{"name":41,"role":37,"phone":26,"phoneExt":26,"email":42},"Sanika Kulkarni, MSc","sanika.kulkarni@psych.ox.ac.uk",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Warneford Hospital, University of Oxford","RECRUITING","Oxford","Oxfordshire","OX37JX","United Kingdom","UK",{"type":53,"coordinates":54},"Point",[55,56],-1.25596,51.75222,{"lat":56,"lon":55},[59,61],{"name":33,"role":37,"phone":60,"phoneExt":26,"email":39},"01865 618320",{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[65],{"name":66,"class":67},"National Institute for Health Research, United Kingdom","OTHER_GOV","100564359","early-phase-1-losartan-and-emotional-learning-100564359",false,"NCT06628154","Losartan and Emotional Learning","The Effects of Single-dose Losartan on Cognitive Flexibility and Learning in Healthy Adults: a Randomised Controlled Study","Inclusion Criteria:\n\n* Willing and able to provide informed consent\n* Aged 18-50 years\n* Score of or below 45 on the Dimensional Anhedonia Rating Scale (DARS; Rizvi et al., 2015)\n* Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires\n* Non- or light-smoker (5 cigarettes a day)\n\nExclusion Criteria:\n\n* Past or present DSM-5 axis-I diagnosis (based on SCID results at screening) other than anxiety disorder, dysthymia or unipolar depression\n* First-degree family member with severe psychiatric illness\n* CNS-medication last 6 weeks (including as part of another study)\n* Current blood pressure or other heart medication (especially aliskiren or beta blockers)\n* Diagnosis of intravascular fluid depletion or dehydration\n* History of angioedema\n* Impaired kidney function (based on self-report)\n* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90\u002F50 mmHg (in accordance with established standard definitions: DOI 10.1186\u002Fs12887-016-0633-7))\n* Lifetime history of epilepsy or other neurological disease (e.g. autism, ADHD)\n* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study\n* Significant loss of hearing that is not corrected with a hearing device\n* Women: pregnancy, breast-feeding",true,"ALL","18 Years","50 Years",{"count":80,"type":81},60,"ESTIMATED","INTERVENTIONAL",[84],"EARLY_PHASE1","This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in healthy volunteers.",[87],"Emotional Processing",[89,90,91,92],"emotional processing","reward","anxiety","depression","2024-10-02",{"date":95,"type":96},"2024-10-04","ACTUAL",{"date":98,"type":96},"2024-08-14",{"date":100,"type":81},"2025-07",{"name":5,"class":6},1]